ID   ER-Cal-27
AC   CVCL_EI26
DR   GEO; GSM1519077
DR   GEO; GSM1519078
DR   GEO; GSM1519079
DR   Wikidata; Q54832416
RX   PubMed=25888065;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:114785; Erlotinib.
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.His193Leu (c.578A>T); ClinVar=VCV000185822; Zygosity=Unspecified (from parent cell line).
CC   Omics: Transcriptome analysis by microarray.
CC   Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
DI   NCIt; C173807; Tongue adenosquamous carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_1107 ! CAL-27
SX   Male
AG   56Y
CA   Cancer cell line
DT   Created: 26-09-16; Last updated: 29-06-23; Version: 14
//
RX   PubMed=25888065; DOI=10.1016/j.molonc.2015.03.008;
RA   Stanam A., Love-Homan L., Joseph T.S., Espinosa-Cotton M.,
RA   Simons A.L.;
RT   "Upregulated interleukin-6 expression contributes to erlotinib
RT   resistance in head and neck squamous cell carcinoma.";
RL   Mol. Oncol. 9:1371-1383(2015).
//